| Heading: |
Neuroendocrine Cancer: Radiotherapy |
| Question ID: |
1811693 |
| UIN: |
59175 |
| House: |
Commons |
| Date tabled: |
2025-06-11 |
| Asking Member ID: |
5359 |
| Asking Member display name: |
Neil Duncan-Jordan
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Neil Duncan-Jordan
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of the potential merits of commissioning selective internal radiation therapy for patients with neuroendocrine tumours. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-19 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Radiotherapy treatment for cancer is highly individualised and decisions about cancer treatment are typically made by clinicians and multidisciplinary teams of healthcare professionals. They consider all aspects of a patient's health and circumstances whe... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |